AptarGroup Inc (ATR)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE
Market Cap: $9.07B
Last updated: Nov 17, 2026 at 11:04 AM ET
AptarGroup Inc (ATR) Earnings: Report Dates and Results
AptarGroup (ATR) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, AptarGroup reported EPS of $1.52, above the $1.46 estimate. It beat the EPS estimate in each of the last 17 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ATR has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 15.2% above the $1.25 reported for the quarter ended Dec 31, 2025.
ATR Earnings Call
The latest ATR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, ATR beat 34, missed 3 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $1.02B, up 6.1% from $961.13M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.52 | $1.46 | $1.45 - $1.49 | +4.11% | Beat | -6.2% | 8 | 0 up, 1 down | Oct 29, 2026 | $1.02B |
| Jun 30, 2026 | $1.42 | $1.34 | $1.33 - $1.38 | +5.97% | Beat | -14.5% | 7 | N/A | Jul 30, 2026 | $1.03B |
| Mar 31, 2026 | $1.19 | $1.15 | $1.14 - $1.18 | +3.48% | Beat | -0.8% | 7 | 0 up, 3 down | Apr 30, 2026 | $982.87M |
| Dec 31, 2025 | $1.25 | $1.23 | $1.20 - $1.27 | +1.63% | Beat | -17.8% | 7 | 0 up, 2 down | Feb 5, 2026 | $962.74M |
| Sep 30, 2025 | $1.62 | $1.57 | $1.54 - $1.59 | +3.18% | Beat | +8.7% | 6 | 2 up, 0 down | Oct 30, 2025 | $961.13M |
| Jun 30, 2025 | $1.66 | $1.59 | $1.57 - $1.60 | +4.40% | Beat | +21.2% | 5 | 0 up, 2 down | Jul 31, 2025 | $966.01M |
| Mar 31, 2025 | $1.20 | $1.16 | $1.13 - $1.19 | +3.45% | Beat | -4.8% | 6 | 1 up, 1 down | May 1, 2025 | $887.30M |
| Dec 31, 2024 | $1.52 | $1.26 | $1.22 - $1.28 | +20.63% | Beat | +25.6% | 6 | 0 up, 3 down | Feb 6, 2025 | $848.09M |
| Sep 30, 2024 | $1.49 | $1.42 | $1.41 - $1.43 | +4.93% | Beat | +7.2% | 5 | 1 up, 0 down | Oct 24, 2024 | $909.29M |
| Jun 30, 2024 | $1.37 | $1.35 | $1.34 - $1.39 | +1.48% | Beat | +11.4% | 5 | 0 up, 0 down | Jul 25, 2024 | $910.06M |
| Mar 31, 2024 | $1.26 | $1.15 | $1.11 - $1.18 | +9.57% | Beat | +32.6% | 5 | 0 up, 0 down | Apr 25, 2024 | $915.45M |
| Dec 31, 2023 | $1.21 | $1.12 | $1.10 - $1.13 | +8.04% | Beat | +31.5% | 5 | 0 up, 0 down | Feb 8, 2024 | $838.48M |
| Sep 30, 2023 | $1.39 | $1.27 | $1.25 - $1.29 | +9.45% | Beat | +46.3% | 5 | 1 up, 1 down | Oct 25, 2023 | $893.00M |
| Jun 30, 2023 | $1.23 | $1.14 | $1.11 - $1.16 | +7.89% | Beat | +28.1% | 6 | 2 up, 0 down | Jul 27, 2023 | $895.91M |
| Mar 31, 2023 | $0.95 | $0.90 | $0.88 - $0.92 | +5.56% | Beat | -1.0% | 7 | 0 up, 0 down | Apr 27, 2023 | $860.07M |
| Dec 31, 2022 | $0.92 | $0.79 | $0.78 - $0.82 | +16.46% | Beat | -1.1% | 8 | 1 up, 0 down | Feb 16, 2023 | $795.91M |
| Sep 30, 2022 | $0.95 | $0.94 | $0.87 - $1.00 | +1.06% | Beat | +1.1% | 9 | 0 up, 2 down | Oct 27, 2022 | $836.86M |
| Jun 30, 2022 | $0.96 | $0.96 | $0.90 - $1.01 | 0.00% | In line | +5.5% | 9 | 0 up, 1 down | Jul 28, 2022 | $844.54M |
| Mar 31, 2022 | $0.96 | $0.96 | $0.93 - $0.98 | 0.00% | In line | -11.9% | 9 | 0 up, 2 down | Apr 28, 2022 | $844.93M |
| Dec 31, 2021 | $0.93 | $0.91 | $0.88 - $0.94 | +2.20% | Beat | +1.1% | 9 | 0 up, 0 down | Feb 17, 2022 | $813.99M |
| Sep 30, 2021 | $0.94 | $0.94 | $0.91 - $0.97 | 0.00% | In line | -6.0% | 10 | N/A | Oct 28, 2021 | $825.44M |
| Jun 30, 2021 | $0.91 | $0.97 | $0.92 - $1.02 | -6.19% | Miss | +13.7% | 10 | N/A | Jul 29, 2021 | $811.03M |
| Mar 31, 2021 | $1.09 | $0.90 | $0.84 - $0.94 | +21.11% | Beat | +17.2% | 10 | N/A | Apr 29, 2021 | $776.75M |
| Dec 31, 2020 | $0.92 | $0.90 | $0.88 - $0.94 | +2.22% | Beat | +15.0% | 10 | N/A | Feb 18, 2021 | $749.33M |
| Sep 30, 2020 | $1.00 | $0.84 | $0.80 - $0.88 | +19.05% | Beat | +7.5% | 10 | N/A | Oct 29, 2020 | $759.15M |
| Jun 30, 2020 | $0.80 | $0.66 | $0.57 - $0.76 | +21.21% | Beat | -30.4% | 9 | N/A | Jul 30, 2020 | $699.30M |
| Mar 31, 2020 | $0.93 | $0.87 | $0.83 - $0.92 | +6.90% | Beat | -13.1% | 9 | N/A | Apr 30, 2020 | $721.55M |
| Dec 31, 2019 | $0.80 | $0.78 | $0.76 - $0.80 | +2.56% | Beat | -13.0% | 9 | N/A | Feb 20, 2020 | $671.33M |
| Sep 30, 2019 | $0.93 | $0.95 | $0.94 - $0.98 | -2.11% | Miss | -6.1% | 11 | N/A | Oct 31, 2019 | $701.28M |
| Jun 30, 2019 | $1.15 | $1.13 | $1.12 - $1.15 | +1.77% | Beat | +5.5% | 12 | N/A | Jul 31, 2019 | $742.66M |
| Mar 31, 2019 | $1.07 | $0.98 | $0.97 - $1.00 | +9.18% | Beat | +8.1% | 11 | N/A | Apr 30, 2019 | $744.46M |
| Dec 31, 2018 | $0.92 | $0.85 | $0.83 - $0.86 | +8.24% | Beat | +13.6% | 11 | N/A | Feb 20, 2019 | $685.03M |
| Sep 30, 2018 | $0.99 | $0.93 | $0.90 - $0.95 | +6.45% | Beat | +28.6% | 11 | N/A | Nov 1, 2018 | $665.77M |
| Jun 30, 2018 | $1.09 | $1.01 | $1.00 - $1.03 | +7.92% | Beat | +7.9% | 11 | N/A | Jul 26, 2018 | $710.61M |
| Mar 31, 2018 | $0.99 | $0.93 | $0.91 - $0.94 | +6.45% | Beat | +22.2% | 9 | N/A | Apr 26, 2018 | $703.35M |
| Dec 31, 2017 | $0.81 | $0.70 | $0.68 - $0.72 | +15.71% | Beat | +17.4% | 9 | N/A | Feb 12, 2018 | $625.89M |
| Sep 30, 2017 | $0.77 | $0.80 | $0.78 - $0.82 | -3.75% | Miss | -6.1% | 9 | N/A | Oct 26, 2017 | $624.33M |
| Jun 30, 2017 | $1.01 | $0.96 | $0.94 - $1.01 | +5.21% | Beat | +11.0% | 10 | N/A | Jul 27, 2017 | $617.75M |
| Mar 31, 2017 | $0.81 | $0.75 | N/A | +8.00% | Beat | +14.1% | N/A | N/A | Apr 27, 2017 | $601.32M |
| Dec 31, 2016 | $0.69 | $0.66 | N/A | +4.55% | Beat | +3.0% | N/A | N/A | Feb 9, 2017 | $538.87M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $5.73, up 1.6% from the year before. It was $3.13 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $5.73 | +1.6% |
| Dec 31, 2024 | $5.64 | +18.0% |
| Dec 31, 2023 | $4.78 | +26.1% |
| Dec 31, 2022 | $3.79 | -2.1% |
| Dec 31, 2021 | $3.87 | +6.0% |
| Dec 31, 2020 | $3.65 | -7.6% |
| Dec 31, 2019 | $3.95 | N/A |
| Dec 31, 2018 | $3.99 | +17.4% |
| Dec 31, 2017 | $3.40 | +8.6% |
| Dec 31, 2016 | $3.13 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,800 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,764 | 12 | |
| 2026Q2 | Jun 30, 2026 | 6,621 | 10 | |
| 2026Q1 | Mar 31, 2026 | 6,530 | 12 | |
| 2025Q4 | Dec 31, 2025 | 7,533 | 11 | |
| 2025Q3 | Sep 30, 2025 | 6,599 | 11 | |
| 2025Q2 | Jun 30, 2025 | 6,492 | 9 | |
| 2025Q1 | Mar 31, 2025 | 6,853 | 10 | |
| 2024Q4 | Dec 31, 2024 | 6,875 | 9 |
2026Q3 Earnings Call
Opening remarks
Mary Skafidas Senior Vice President, Investor Relations and Communications Hello, everyone. Good morning, and thanks for being with us on our call today. Joining me on today's call are Gael Touya, President and CEO, and Vanessa Kanu, Executive Vice President and CFO. Our press release and accompanying slide deck have been posted on our website under the Investor Relations page. During this call, we will be discussing certain non-GAAP financial measures. These measures are reconciled to the most directly comparable GAAP financial measure, and the reconciliations are set forth in the press release. Please refer to the press release disseminated yesterday for reconciliations of non-GAAP measures to the most comparable GAAP measures discussed during this earnings call. As always, we will post a replay of this call on our website. I would now like to turn the conference call over to Gael.
Gael Touya President and CEO Thank you, Mary, and good morning, everyone. I'm pleased to join you today for my first earnings call as CEO of Aptar. I will touch on the quarter briefly and then turn it over to Vanessa to add more details. Our results in the quarter demonstrate the underlying strength of our businesses, with 5% core sales growth across all three segments and adjusted earnings per share at the higher end of our guidance range. Our adjusted EBITDA margin of 21.3% remained within our long-term target range, despite emergency medicine destocking and the associated mix impact. In Pharma, while the anticipated reduction in emergency medicine sales continues to affect our growth rate, the underlying business remains strong. Results were driven by broad-based demand across a number of end markets in each of our divisions. This breadth is important. Our Pharma growth opportunities are not dependent on one product or one therapeutic category. It reflects the depth of our portfolio, innovation pipeline, and the increasingly important role Aptar plays with customers across the drug development cycle. Our ambition is to continue moving forward, becoming the partner of choice for our customers through our technology, scientific expertise, services, and regulatory capabilities. Beauty also delivered strong top-line growth in the quarter, with strong demand from a number of end markets, including prestige fragrance and color cosmetics. But looking at profitability, I want to be clear. Sales growth alone is not our objective. Our goal is to convert the strong demand for our products into more consistent profitability. We have excellent technology, strong customer relationships, and leading positions in attractive categories. At the same time, the margin performance, mostly in North America, is not where it needs to be. Closures also delivered double-digit core sales growth, reflecting strong demand in beverage and food and continued momentum from innovation.
Frequently Asked Questions About ATR
When is AptarGroup's next earnings date?
AptarGroup's next earnings report is expected for Feb 3, 2027.
Did ATR beat earnings estimates last quarter?
Yes. AptarGroup reported EPS of $1.52 for the quarter ended Sep 30, 2026, above the $1.46 estimate, a 4.11% surprise.
What EPS do analysts expect from ATR next quarter?
The consensus EPS estimate for AptarGroup for the quarter ending Dec 31, 2026 is $1.44 from 10 analysts, with estimates from $1.38 to $1.51.
How often does ATR beat earnings estimates?
AptarGroup beat the EPS estimate in each of the last 17 quarters, with an average surprise of +6.55%.
ATR pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts